[Treatment and prognosis of brain metastases from XXXX : A retrospective study].

@entity1 @entity2663 @entity1149 @entity900 @entity3
BACKGROUND: Now the treatment of @entity1149 ( @entity1149 ) @entity1 with brain @entity3 is not a standard program. The aim of this study is to summarize the factors related to survival of @entity1 with brain metastases from @entity1149 . METHODS: A total of 111 @entity1149 @entity1 with brain metastases (from September 1995-May 2004) were defined as symptomatic group (37 @entity1 ) and asymptomatic group (74 @entity1 ) according to central nervous system (CNS) symptoms. The @entity1 in the symptomatic group were given whole brain radiation therapy (WBRT, DT 30-40Gy/20f) first, and then received @entity900 -based chemotherapy. The @entity1 in the asymptomatic group were given @entity900 -based chemotherapy first, and then received WBRT. During the treatment, 49 @entity1 received chemotherapy of BCNU or @entity2663 irregularly. RESULTS: The median survival time was 11 months. The 1-and 2-year survival rate was 40.79% and 13.26% respectively. The survival time was not significantly different between the symptomatic group and asymptomatic group. Median chemotherapy of asymptomatic group was 3 cycles (1-6 cycles) before WBRT. Those @entity1 who received 3 or 4 cycles of chemotherapy before WBRT had better survival (P= 0.0188 , P=0.0035). The treatment of BCNU or @entity2663 was a benefit factor for survival (P=0.0219) in asymptomatic group. The hematologic toxicity of grade III or IV was not significantly different between the two groups (P > 0.05). The number of brain @entity3 (P=0.000), extracranial @entity3 (P=0.022) and WHO performance status (P=0.001) were independent prognostic factors. CONCLUSIONS: The @entity1 with asymptomatic brain metastases receive 3-4 cycles of chemotherapy before WBRT may be reasonable. During the therapy, the @entity1 with administration of BCNU or @entity2663 may have survival benefit.
